GNRH1 and prostate cancer: Cetrorelix acetate was the first GnRH antagonist on the market and is used to prevent premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation, whereas triptorelin pamoate received approval for the palliative treatment of advanced prostate cancer [10,11,12].